Eurofins Lancaster Laboratories has launched a new validated Rapid Mycoplasma Detection Test, designed to overcome time-consuming challenges associated with 28-day compendial method for mycoplasma testing. For GMP and non-GMP assays, Eurofins can deliver same-day preliminary results, while ensuring rapid, robust and reliable culture-free mycoplasma detection that is less prone to matrix interferences, according to the company. The company uses EMD Millipore’s MilliPROBE Real Time Detection System for Mycoplasma to execute this rapid technology.
 
“Traditional mycoplasma testing procedures are time consuming, requiring a 28-day duration; however, this time requirement is not amenable for obtaining the rapid lot release testing results needed for biopharmaceutical products that have short half-lives or those that are in high market demand,” said Dr. Jeri Ann Boose, director of Biopharmaceutical Services at Eurofins Lancaster Laboratories. “The lengthy assay period is also not conducive to the rapid screening of raw materials intended for use in future production, nor to the rapid in-process screening of intermediates for the purpose of detecting and containing contamination events. Our new assay eliminates clients’ fast turnaround time challenges.”
 
The new rapid mycoplasma test meets European Pharmacopeia 2.6.7 guidelines, and is comparable in sensitivity to the 28-day culture-based compendial method, according to the company. Also, Millipore’s MilliPROBE Real Time Detection System is capable of processing volumes of material comparable to the compendial method.